Table 1

Clinical, pathological and molecular characteristics of colon cancer patients in the two cohorts of treatment
Frequency N (%)
Surgery alone (n = 60; 50%) 5-FU therapy (n = 60; 50%) p
Clinical-pathological features Age, mean (SD), years 67.4 (10.44) 67.7 (10.8) 0.9
Sex Male 28 (47) 29 (48) 0.3
Female 32 (53) 31 (52)
Tumour location1 Proximal 21 (35) 25 (42) 0.4
Distal 39 (65) 35 (58)
Tumour grade G1 8 (13) 8 (13) 0.5
G2 51 (85) 49 (82)
G3 1 (2) 3 (5)
Depth of tumour invasion pT3 53 (88) 53 (88) 1.0
pT4 7 (12) 7 (12)
Lymphovascular invasion No 39 (65) 37 (62) 0.8
Yes 21 (35) 22 (38)
Large veins invasion No 51 (85) 47 (78) 0.3
Yes 9 (15) 13 (22)
Tumour infiltrating lymphocytes No 53 (88) 48 (80) 0.2
Yes 7 (12) 12 (20)
Chron’s like reaction No 31 (52) 27 (45) 0.4
Yes 29 (48) 33 (55)
Tumour border configuration Pushing 56 (93) 51 (85) 0.2
Infiltrating 4 (7) 9 (15)
Molecular parameters MMR system dMMR 8 (13) 10 (17) 0.6
pMMR 52 (87) 50 (83)
CIMP CIMP-High 8 (13) 14 (23) 0.3
CIMP-Low 18 (30) 18 (30)
CIMP-0 34 (57) 28 (47)
TYMS mRNA expression High level 24 (40) 33 (55) 0.1
Low level 36 (60) 27 (45)
TYMS protein expression (IHC) High 30 (50) 28 (47) 0.7
Low 30 (50) 32 (53)
TP53 Positive 24 (40) 22 (37) 0.7
Negative 36 (60) 38 (63)
CTNNB12 Cytoplasmic localization Positive 41 (68) 41 (69) 0.8
Negative 19 (32) 18 (31)
CTNNB12 Nuclear localization Positive 18 (30) 26 (44) 0.1
Negative 42 (70) 33 (56)
CTNNB12 Membrane localization Positive 27 (45) 19 (32) 0.1
Negative 33 (55) 40 (68)
BRAF c.1799 T > A Wild type 51 (85) 52 (87) 1.0
Mutated 9 (15) 8 (13)

1: Proximal colon includes cecum to transverse colon and distal colon includes splenic flexure to sigmoid colon.

2: One of the 60 cases treated with 5-FU was excluded from the analysis because of poor staining.

Donada et al.

Donada et al. BMC Gastroenterology 2013 13:36   doi:10.1186/1471-230X-13-36

Open Data